The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

[powerpress]

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

[powerpress]

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

[powerpress]

The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

[powerpress]

"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

[powerpress]

Lung cancer patients with high MET amplification appear to do well on Xalkori (crizotinib), a drug that is approved for ALK positive patients.

[powerpress]

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

[powerpress]

EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

[powerpress]

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

[powerpress]

Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?

[powerpress]